NCT00390117 - AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 5, 2007

Primary Completion Date

March 13, 2012

Study Completion Date

January 10, 2013

Conditions

LymphomaUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

CDKI AT7519

AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.

OTHER

laboratory biomarker analysis

Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.

Trial Locations (2)

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto